RocketTheme Joomla Templates
     
Emissary Home Articles Emissary in the Clinical Research Press

Emissary Contract Research Organization Featured Articles

Clinical Trial Outsourcing Emerging as a Key Trend in Drug Research And Development Markets

Emissary in the Clinical Research Press

TORONTO, Nov. 12 /PRNewswire/ --

Contract research organizations (CROs) are a growing trend among the pharmaceutical and biotechnology sectors as these companies look to reduce the costs of drug development. However, there are tradeoffs between the size of a CRO and the therapeutic and local expertise dedicated to individual projects.

Read more...
 

Emissary Technology Key to Enrolling First Patient Within 7 Days of FDA Approval of a Dialysis Graft Trial

Emissary in the Clinical Research Press

Emissary Inc. has been selected by Novoste Corporation (Nasdaq:NOVT) to collaborate on monitoring and clinical trial management of Novoste's BRAVO (Beta Radiation for treatment of Arterial-Venous graft Outflow) clinical trial.

Read more...
 

Emissary Presents at Southwest Equity Capital Summit

AUSTIN, Texas -- Emissary Inc. today announced that it will participate in the 2002 Southwest Equity Capital Summit organized by the Capital Network October 2-3 in Richardson, Texas. Steven Mayo, founder and CEO of Emissary, will present the company's plans to streamline drug and medical device research studies with a new Web-based software initiative.

Read more...
 

Clinical Trial Accrual Hampered by Many Factors

Articles - Emissary in the Clinical Research Press
Written by Healthcare Advisory Board   

In recent years, cancer patients are more knowledgeable and willing to participate in clinical trials, but issues pertaining to physician enthusiasm, design requirements, and enrollment procedures now pose large barriers to patient accrual, finds two new Cancer studies. Since previous research has predominantly focused on patient and physician perspectives, Canadian researchers interviewed clinical research associates (CRAs), whose work spans all stages of clinical trials, to gain new insight into the factors influencing enrollment. The CEO of an Austin, Texas-based contract research organization (CRO), which designs trials and staffs CRAs, told the Watch (9/24/02) that the strict participation guidelines for oncology-related clinical trials make meeting accrual goals for experimental cancer therapies particularly difficult.

Read more...
 

Contact Emissary

business phone system

1000 characters left

Captcha imageReload image



Recent Articles

FDA Form 1572 - Guidance on the FDA's Statement of Investigator Form

In July 2008, FDA released a draft guidance to answer frequent questions about Form...

Illuminating the Diagnosis of Intracranial Hematoma

Without urgent pressure-relieving surgery, the chance of survival drops quickly for head trauma patients...

FDA’s Bioresearch Monitoring (BIMO) Inspections

BIMO, the Bioresearch Monitoring Program, is a Food and Drug Administration (FDA) program of on-site...

module by Inspiration